정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2389 | Not yet recruiting | A Study of RLS-0071 in Patients With Acute Lung Injury Due to COVID-19 Pneumonia in Early Respiratory Failure | COVID-19 | Drug: RLS-0071 Drug: RLS-0071 Drug: Placebo Drug: RLS-0071 Drug: RLS-0071 Drug: Placebo |
Phase 1 | ReAlta Life Sciences, Inc. | INDUSTRY | 42 | All | 18 Years ~ 69 Years | Prestige Clinical Research Center, Coral Gables, Florida, United States |
| 2388 | Not yet recruiting | A Study of Safety and Immunogenicity of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adults With Chronic Immune-Mediated Diseases | COVID-19 | Biological: CpG 1018/Alum-adjuvanted SCB-2019 vaccine Biological: Havrix Other: Placebo; 0.9% saline |
Phase 3 | Clover Biopharmaceuticals AUS Pty Ltd | INDUSTRY | 300 | All | 18 Years | Brandwag, Bloemfontein, Brandwag, Bloemfontein, South Africa Cape Town, Cape Town, South Africa Kyiv, Kyiv, Ukraine Kyiv, Kyiv, Ukraine |
| 2387 | Recruiting | A Study of SARS CoV-2 Infection and Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine | SARS-CoV-2 Infection | Biological: Moderna COVID-19 Vaccine | Phase 3 | National Institute of Allergy and Infectious Diseases (NIAID) | NIH | 37500 | All | 18 Years ~ 29 Years | Alabama CRS, Birmingham, Alabama, United States Headlands Research Scottsdale, Scottsdale, Arizona, United States AMR Phoenix, Tempe, Arizona, United States University of Arizona, Tucson, Arizona, United States Charles Drew University, Los Angeles, California, United States UC Davis, Sacramento, California, United States University of California, San Diego, San Diego, California, United States University of Colorado- Boulder, Boulder, Colorado, United States JEM Headlands LLC, Atlantis, Florida, United States University of Florida, Gainesville, Florida, United States UF CARES, Jacksonville, Florida, United States Orlando Immunology Center CRS, Orlando, Florida, United States Headlands Research Sarasota, Sarasota, Florida, United States University of South Florida, Tampa, Florida, United States Morehouse University, Atlanta, Georgia, United States The Hope Clinic of the Emory Vaccine Center CRS, Decatur, Georgia, United States Champaign-Urbana Public Health District, Champaign, Illinois, United States Rush University CRS, Chicago, Illinois, United States Northwestern University, Evanston, Illinois, United States Indiana University, Bloomington, Indiana, United States Univ, of Kansas School of Medicine CRS, Wichita, Kansas, United States University of Kentucky, Lexington, Kentucky, United States Centex Studies, Inc. - Lake Charles, Lake Charles, Louisiana, United States University of Maryland College Park, College Park, Maryland, United States Fenway Health (FH) CRS, Boston, Massachusetts, United States Wayne State - Harper Hospital, Detroit, Michigan, United States University of Minnesota, Minneapolis, Minnesota, United States Columbia - Missouri VTEU, Columbia, Missouri, United States The Children's Mercy Hospital, Kansas City, Missouri, United States Washington University Therapeutics CRS, Saint Louis, Missouri, United States University of Nebraska, Omaha, Nebraska, United States AMR Las Vegas, Las Vegas, Nevada, United States University of New Mexico, Albuquerque, New Mexico, United States Bronx Prevention Research Center CRS, Bronx, New York, United States NYU Long Island Vaccine Center, Mineola, New York, United States NYU Bellevue Vaccine Center, New York, New York, United States Harlem Prevention Center CRS, New York, New York, United States New York Blood Center CRS, New York, New York, United States Stony Brook University, Stony Brook, New York, United States University of North Carolina, Chapel Hill, North Carolina, United States Wake Forest University, Winston-Salem, North Carolina, United States Penn Prevention CRS, Philadelphia, Pennsylvania, United States The Miriam Hopsital CRS, Providence, Rhode Island, United States Clemson University, Clemson, South Carolina, United States Vanderbilt Vaccine CRS, Nashville, Tennessee, United States Texas Tech, Amarillo, Texas, United States Centex Studies, Inc. - Brownsville, Brownsville, Texas, United States Texas A&M University, College Station, Texas, United States Centex Studies, Inc. - Houston, Houston, Texas, United States Centex Studies, Inc. - Westfield, Houston, Texas, United States Texas A&M - Kingsville, Kingsville, Texas, United States Centex Studies, Inc. - McAllen, McAllen, Texas, United States University of Virginia, Charlottesville, Virginia, United States University of Washington, Seattle, Washington, United States West Virginia University, Morgantown, West Virginia, United States |
| 2386 | Active, not recruiting | A Study of TAK-019 in Healthy Japanese Adults (COVID-19) | Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) | Biological: TAK-019 Biological: Placebo |
Phase 2 | Takeda | INDUSTRY | 200 | All | 20 Years | Sumida Hospital, Sumida-ku, Tokyo, Japan Nishi Kumamoto Hospital, Kumamoto, Japan |
| 2385 | Active, not recruiting | A Study of TAK-919 in Healthy Japanese Adults (COVID-19) | Prevention of Infectious Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) | Biological: TAK-919 Biological: Placebo |
Phase 2 | Takeda | INDUSTRY | 200 | All | 20 Years | Sumida Hospital, Sumida-ku, Tokyo, Japan PS Clinic, Fukuoka, Japan |
| 2384 | Not yet recruiting | A Study of the C3 Inhibitor AMY-101 in Patients With ARDS Due to COVID-19 (SAVE) | Acute Respiratory Distress Syndrome Due to SARS-CoV-2 Infection (Severe COVID19) | Drug: AMY-101 Other: WFI 5% glucose |
Phase 2 | Amyndas Pharmaceuticals S.A. | INDUSTRY | 144 | All | 18 Years | |
| 2383 | Completed | A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19 | Respiratory Failure | Drug: Mefloquine Drug: Hydroxychloroquine Combination Product: Mefloquine + azithromycin + / - tocilizumab Combination Product: Hydroxychloroquine + azithromycin + / - tocilizumab |
Phase 3 | Burnasyan Federal Medical Biophysical Center | OTHER_GOV | 320 | All | 18 Years ~ 60 Years | Burnasyan Federal Medical Biophysical Center FMBA of Russia, Moscow, Russian Federation |
